reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Free base form |
| Molecular mass | Approximately 4813 Da | Calculated from the sequence |
| Amino acid residues | 39 | GIP-derived backbone |
| Receptor targets | GIP and GLP-1 | Dual agonist |
| Circulating half-life | About 5 days | Supports weekly administration |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
It has also been shown to possess significant neutralizing activity against gram-positive and gram-negative bacteria, with slightly higher activity against gram-positive organisms. Many plant derived compounds have demonstrated potential as therapeutic tools. In one study sugiol showed efficacy in treating Leishmania infantum, a parasite that can cause Leishmaniasis in humans. Free sugiol was able to induce cell-death in the parasitic bacteria, and when encased in cell walls obtained from yeast was able to enter a parasitized macrophage and inhibit the L. infantum within. Because sugiol has shown so many protective effects in therapeutic trials, it is likely that in plants it acts as a chemical defense agent. Sugiol present in the resins of conifers may help to protect the plant against ROS generated during metabolism, as well as against any pathogenic viruses or bacteria.
==== Agriculture ==== When a soil becomes too dry, plant transpiration drops because the water is increasingly bound to the soil particles by suction. Below the wilting point plants are no longer able to extract water. At this point they wilt and cease transpiring altogether. Conditions where soil is too dry to maintain reliable plant growth is referred to as agricultural drought, and is a particular focus of irrigation management. Such conditions are common in arid and semi-arid environments. Some agriculture professionals are beginning to use environmental measurements such as soil moisture to schedule irrigation. This method is referred to as smart irrigation or soil cultivation.
==== Liquid–liquid or solvent extraction ==== Liquid–liquid extraction or solvent extraction can be used to isolate YTXs from the sample medium. Methanol is normally the solvent of choice, but other solvents can also be used including acetone and chloroform. The drawback of using the solvent extraction method is the levels of analyte recovery can be poor, so any results obtained from the quantification processes may not be representative of the sample.
Emopamil binding protein is a protein that in humans is encoded by the EBP gene, located on the X chromosome. EBP was discovered through its high-affinity binding to anti-ischemic drugs such as emopamil, from which it also derives its name. In addition to emopamil, EBP also bind with high affinity a variety of structurally unrelated compounds, such as amiodarone, opipramol, ifenprodil, trifluoperazine, and chlorpromazine. EBP has a mass of 27.3 kDa and resembles the σ2-receptor that resides in the endoplasmic reticulum of various tissues as an integral membrane protein.
Sources: en.wikipedia.org
Winning percentage: 70.5% at International circuit & 78.9% at National circuit Podium percentage: 86.9% at International circuit & 94.7% at National circuit Top 5 percentage: 95.1% at International circuit & 100.0% at National circuit
When fungal spores germinate, they initially form preliminary associations with common free-living algae in their vicinity. Additionally, the fungus can recruit compatible algal cells from neighboring lichen thalli—essentially extracting these partners—to help establish a complete symbiotic relationship. Native across Europe, parts of Asia, and coastal North Africa, X. parietina has a more limited and primarily coastal distribution in North America and Australia, where genetic evidence suggests human-mediated introduction. In recent decades, it has expanded inland in these regions, particularly in urban environments and areas affected by agricultural runoff, road salt application, and nitrogen deposition. The lichen grows slowly (averaging 2.6 mm (1⁄8 in) per year) but possesses considerable regenerative abilities, with fragments capable of developing into new thalli. It participates in a complex web of ecological interactions, hosting at least 41 species of lichen-dwelling fungi, while certain gastropods and microscopic rotifers contribute to its dispersal by consuming and excreting viable spores. The species has high diversity even within local populations, with distinct patterns linked to both geographic location and substrate type. This genetic variability, combined with the lichen's flexible associations with different photobiont strains, contributes to its ecological success. X. parietina serves as a bioindicator for monitoring air quality due to its capacity to accumulate environmental contaminants.
Acetoxolutamide is a nonsteroidal androgen and selective androgen receptor modulator (SARM) which was described in 2000 and was never developed or marketed for medical use. It was derived from structural modification of the nonsteroidal antiandrogen bicalutamide and the nonsteroidal SARM acetothiolutamide. Acetoxolutamide shows greatly improved pharmacokinetic properties and anabolic and androgenic potency relative to acetothiolutamide in animals. It is the (2R) enantiomer of andarine (also known as acetamidoxolutamide or androxolutamide).
Diprenorphine, also known as diprenorfin and sold under the brand name Revivon, is a non-selective, high-affinity, weak partial agonist of the μ- (MOR), κ- (KOR), and δ-opioid receptor (DOR) (with equal affinity) which is used in veterinary medicine as an opioid antagonist. It is used to reverse the effects of super-potent opioid analgesics such as etorphine and carfentanil that are used for tranquilizing large animals. The drug is not approved for use in humans. Diprenorphine was the preferred reversal for etorphine but today naltrexone is preferred due to being a full antagonist. Effects occur within 1–3 minutes when given IV and 15–20 minutes given IM. Diprenorphine is the strongest opioid antagonist that is commercially available (some 100 times more potent than nalorphine), and is used for reversing the effects of very strong opioids for which the binding affinity is so high that naloxone does not effectively or reliably reverse the narcotic effects. Diprenorphine is used as a reversal agent for etorphine and carfentanil, and is normally used to remobilise animals once veterinary procedures have been completed. Since diprenorphine also has partial agonistic properties of its own, it should not be used on humans if they are accidentally exposed to etorphine or carfentanil. Naloxone or naltrexone is the preferred human opioid receptor antagonist. Because diprenorphine is a weak partial agonist of the opioid receptors rather than a silent antagonist, it can produce some opioid effects in the absence of other opioids at sufficient doses.
Smith was hired to become the defensive quality control coach for the Tennessee Titans in 2011 under new head coach Mike Munchak. Smith then became the offensive quality coach the following season. In 2013, Smith was promoted to the assistant offensive line and assistant tight ends coach. Munchak was fired after the 2013 season and new head coach Ken Whisenhunt retained Smith as the assistant tight ends coach. Midway through the 2015 season, Whisenhunt was fired and replaced by tight ends coach Mike Mularkey. Mularkey was kept as head coach for the 2016 season and Smith was promoted to the new tight ends coach. When Mularkey was fired after the 2017 season, new head coach Mike Vrabel kept Smith as the tight ends coach for 2018. On January 21, 2019, Smith was promoted to offensive coordinator, replacing Matt LaFleur, who departed to become head coach of the Green Bay Packers two weeks prior. In his first year as offensive coordinator, Smith oversaw the highest-scoring Titans team in 16 years, with Derrick Henry, Ryan Tannehill, and Jonnu Smith having career years. Smith was praised for his play-calling in the Titans' 28–12 road victory over the top-seeded Baltimore Ravens in the AFC Divisional Round. In 2020, the Titans ranked fourth in scoring and second in total yards.
Sources: en.wikipedia.org
An NTP binding site is a type of binding site found in nucleoside monophosphate (NMP) kinases, N can be adenosine or guanosine. A P-loop is one of the structural motifs common for nucleoside triphosphate (NTP) binding sites, it interacts with the bound nucleotide's phosphoryl groups. For the binding site to be able to bind a nucleotide, the nucleotide must be complex bound to Mg2+ or Mn2+. Nucleotide binding will cause conformational changes in the protein because the P-loop will bend. NTP binding sites play a role in poliovirus RNA replication. On the poliovirus RNA-dependent polymerase, also known as 3Dpol, there are two binding sites. Both binding sites contain lysine residues; however, only the lysine at position 61 is essential for RNA sequence elongation as part of the replication process. Additionally, a method known as computational alanine mutagenesis, has been used to find the key portions within the amino acid sequences that majorly characterize a particular NTP binding site; these regions within the sequence are conserved.
It has been shown that endoglin expression and TGF-beta secretion are attenuated in bone marrow stromal cells when they are cocultured with prostate cancer cells. Also, the downstream TGF-beta/bone morphogenic protein (BMP) signaling pathway, which includes Smad1 and Smad2/3, were attenuated along with Smad-dependent gene transcription. Another result in this study was that both Smad1/5/8-dependent inhibitor of DNA binding 1 expression and Smad2/3-dependent plasminogen activator inhibitor I had a reduction in expression and cell proliferation. Ultimately, the cocultured prostate cancer cells altered the TGF-beta signaling in the bone stromal cells, which suggests this modulation is a mechanism of prostate cancer metastases facilitating their growth and survival in the reactive bone stroma. This study emphasizes the importance of endoglin in TGF-beta signaling pathways in other cell types other than endothelial cells. TRC105 is an experimental antibody targeted at endoglin as an anti-angiogenesis treatment for soft-tissue sarcoma. Cluster of differentiation
The addition of 1% cerium dioxide, as in gas mantles, heightens the effect by increasing emissivity in the visible region of the spectrum; but because cerium, unlike thorium, can occur in multiple oxidation states, its charge and hence visible emissivity will depend on the region on the flame it is found in (as such regions vary in their chemical composition and hence how oxidising or reducing they are). Several binary thorium chalcogenides and oxychalcogenides are also known with sulfur, selenium, and tellurium. All four thorium tetrahalides are known, as are some low-valent bromides and iodides: the tetrahalides are all 8-coordinated hygroscopic compounds that dissolve easily in polar solvents such as water. Many related polyhalide ions are also known. Thorium tetrafluoride has a monoclinic crystal structure like those of zirconium tetrafluoride and hafnium tetrafluoride, where the Th4+ ions are coordinated with F− ions in somewhat distorted square antiprisms. The other tetrahalides instead have dodecahedral geometry. Lower iodides ThI3 (black) and ThI2 (gold-coloured) can also be prepared by reducing the tetraiodide with thorium metal: they do not contain Th(III) and Th(II), but instead contain Th4+ and could be more clearly formulated as electride compounds. Many polynary halides with the alkali metals, barium, thallium, and ammonium are known for thorium fluorides, chlorides, and bromides.
Friendly AI are machines that have been designed from the beginning to minimise risks and to make choices that benefit humans. Eliezer Yudkowsky, who coined the term, argues that developing friendly AI should be a higher research priority: it may require a large investment and it must be completed before AI becomes an existential risk. Machines with intelligence have the potential to use their intelligence to make ethical decisions. The field of machine ethics provides machines with ethical principles and procedures for resolving ethical dilemmas. The field of machine ethics is also called computational morality, and was founded at an AAAI symposium in 2005. Geoffrey Hinton has suggested researchers explore instilling human-aligned values, such as compassion, into AI systems as a safeguard, speculating about the possibility of building "maternal instincts" into AI models, so “they really care about people”. Other approaches include Wendell Wallach's "artificial moral agents" and Stuart J. Russell's three principles for developing provably beneficial machines.
== Further reading == Underwood, C.R.; Garibay, P.; Knudsen, L.B.; Peters, G.H.; Rudolph, R. & Reedtz-Runge, S. (January 2010). "Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor". J. Biol. Chem. 285 (1): 723–730. doi:10.1074/jbc.M109.033829. PMC 2804221. PMID 19861722.{{cite journal}}: CS1 maint: multiple names: authors list (link) Nielsen, Malene Løvig (18 December 2015). "Pharmaceutical Researcher is New Honorary Professor at Health". AU.dk. Retrieved 13 May 2024. Lotte Bjerre Knudsen from Novo Nordisk is a new honorary professor at Health, Aarhus University. She is the person behind the discovery of liraglutide, a new class of drugs for Novo Nordisk that are used in the treatment of type 2 diabetes and obesity.
Sources: en.wikipedia.org
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.
A fatty diacid side chain promotes binding to albumin, which delays clearance from circulation. The half-life of roughly five days makes a weekly schedule practical.
No. It is a synthetic peptide whose backbone is based on the natural incretin hormone GIP. Non-natural residues and the lipid side chain were engineered to improve stability and duration of action.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.